Key Takeaways
- • Prenetics' IM8 wellness brand secured $1 billion in growth financing from General Catalyst's Customer Value Fund (CVF), a non-equity debt or structured capital arrangement rather than traditional equity investment.
- • IM8 achieved $100 million in annual recurring revenue (ARR) within 11 months of launch, marking the fastest growth trajectory recorded in the supplements industry.
- • The financing will support scaling operations for IM8, David Beckham's longevity-focused vitamin and wellness drink brand, which generated approximately $60 million in total revenues for fiscal year 2025.
- • General Catalyst closed $8 billion in new capital overall, with the CVF representing a specialized investment vehicle focused on customer value creation rather than equity ownership.
- • IM8 demonstrated accelerating monthly growth, with October revenue increasing 32% month-over-month, signaling sustained momentum in a competitive consumer wellness sector.
Summary
Prenetics Global Limited announced the closing of a $1 billion growth financing arrangement with General Catalyst's Customer Value Fund for its IM8 wellness business. The transaction, disclosed via SEC Form 6-K filing, represents a significant capital infusion to support scaling operations for the longevity-focused supplement and wellness drink brand co-founded by David Beckham.
General Catalyst's Customer Value Fund operates distinctly from traditional venture capital structures—the $1 billion commitment does not constitute equity investment but rather growth capital structured to fund customer acquisition, operational expansion, and market penetration. This distinction is material for institutional investors evaluating the capitalization structure and dilution implications for existing stakeholders in Prenetics Global Limited.
IM8's growth metrics underscore the investment thesis driving the capital commitment. The brand achieved $100 million in annual recurring revenue within 11 months of commercial launch, representing the fastest growth trajectory documented in the supplements and wellness industry. For fiscal year 2025, IM8 generated approximately $60 million in total revenues, with October 2025 revenues growing 32% month-over-month—demonstrating sustained operational momentum and customer acquisition velocity.
The financing announcement aligns with broader capital formation activity at General Catalyst, which closed $8 billion in new capital during the period, including $6 billion for its latest flagship fund (Fund XII) and $2 billion allocated to specialized vehicles including the CVF. The IM8 transaction exemplifies the CVF's thesis of deploying growth capital into high-velocity, customer-centric consumer brands with demonstrated unit economics and retention profiles characteristic of recurring revenue models.
For Prenetics shareholders and alternative investors monitoring consumer wellness sector dynamics, the $1 billion CVF commitment validates market confidence in IM8's longevity positioning and direct-to-consumer distribution capabilities in a category experiencing sustained consumer demand and category expansion.
General Catalyst's Customer Value Fund operates distinctly from traditional venture capital structures—the $1 billion commitment does not constitute equity investment but rather growth capital structured to fund customer acquisition, operational expansion, and market penetration. This distinction is material for institutional investors evaluating the capitalization structure and dilution implications for existing stakeholders in Prenetics Global Limited.
IM8's growth metrics underscore the investment thesis driving the capital commitment. The brand achieved $100 million in annual recurring revenue within 11 months of commercial launch, representing the fastest growth trajectory documented in the supplements and wellness industry. For fiscal year 2025, IM8 generated approximately $60 million in total revenues, with October 2025 revenues growing 32% month-over-month—demonstrating sustained operational momentum and customer acquisition velocity.
The financing announcement aligns with broader capital formation activity at General Catalyst, which closed $8 billion in new capital during the period, including $6 billion for its latest flagship fund (Fund XII) and $2 billion allocated to specialized vehicles including the CVF. The IM8 transaction exemplifies the CVF's thesis of deploying growth capital into high-velocity, customer-centric consumer brands with demonstrated unit economics and retention profiles characteristic of recurring revenue models.
For Prenetics shareholders and alternative investors monitoring consumer wellness sector dynamics, the $1 billion CVF commitment validates market confidence in IM8's longevity positioning and direct-to-consumer distribution capabilities in a category experiencing sustained consumer demand and category expansion.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.